Biomarkers including PD-1 expression, PD-L1 expression, tumour mutation burden and MSI status are not efficient for predicting the benefits of immune checkpoint blockade (Subrahmanyam et al., 2018; Ganesh et al., 2019; Jardim et al., 2021). This evidence concerns the gene CD274 and neoplasm.